Jazz Pharmaceuticals (JAZZ) Net Cash Flow (2010 - 2026)

Jazz Pharmaceuticals' Net Cash Flow history runs 17 years deep, the most recent figure standing at $452.8 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 181.93% year-over-year to $452.8 million in Q1 2026; TTM through Mar 2026 was -$22.0 million, a 105.28% decrease from a year earlier, with the FY2025 full-year figure at -$1.0 billion, down 213.13% from the prior year.
• Net Cash Flow improved to $452.8 million in Q1 2026 per JAZZ's latest filing, from $65.8 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $859.3 million in Q3 2024 and bottomed at -$676.6 million in Q2 2025.
• The 5-year median for Net Cash Flow is $114.4 million (2023), against an average of $73.7 million.
• Across the five-year window, Net Cash Flow surged 1479.44% in 2024 and plunged 802.71% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at $37.2 million in 2022, then soared by 353.98% to $168.8 million in 2023, then grew by 16.7% to $197.0 million in 2024, then plunged by 66.6% to $65.8 million in 2025, then jumped by 588.19% to $452.8 million in 2026.
• Per Business Quant, the three latest JAZZ Net Cash Flow figures stand at $452.8 million (Q1 2026), $65.8 million (Q4 2025), and $136.0 million (Q3 2025).